Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1979 1
1980 2
1982 3
1983 2
1984 4
1985 2
1986 3
1988 5
1989 13
1990 11
1991 16
1992 16
1993 37
1994 27
1995 38
1996 44
1997 59
1998 61
1999 58
2000 80
2001 71
2002 89
2003 100
2004 91
2005 109
2006 106
2007 106
2008 117
2009 133
2010 140
2011 128
2012 115
2013 145
2014 152
2015 143
2016 158
2017 161
2018 157
2019 173
2020 205
2021 214
2022 156
2023 163
2024 213
2025 219
2026 150

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,701 results

Results by year

Filters applied: . Clear all
Page 1
Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies.
Atallah-Yunes SA, Salman O, Robertson MJ. Atallah-Yunes SA, et al. Br J Haematol. 2023 May;201(3):383-395. doi: 10.1111/bjh.18763. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36946218 Review.
Post-transplant lymphoproliferative disorder (PTLD) is rare and heterogeneous lymphoid proliferations that occur as a result of immunosuppression following solid organ transplant (SOT) and haematopoietic stem cell transplant (HSCT) with the majority be
Post-transplant lymphoproliferative disorder (PTLD) is rare and heterogeneous lymphoid proliferations that occur
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Allen UD, et al. Clin Transplant. 2019 Sep;33(9):e13652. doi: 10.1111/ctr.13652. Epub 2019 Jul 23. Clin Transplant. 2019. PMID: 31230381
These updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice review the diagnosis, management, and prevention of post-transplant lymphoproliferative disorders (PTLD) and other Epstein-Barr virus (EBV) …
These updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice review the diagnosis, manage …
Post-transplant lymphoproliferative disorder after solid-organ transplant in children.
Absalon MJ, Khoury RA, Phillips CL. Absalon MJ, et al. Semin Pediatr Surg. 2017 Aug;26(4):257-266. doi: 10.1053/j.sempedsurg.2017.07.002. Epub 2017 Jul 25. Semin Pediatr Surg. 2017. PMID: 28964482 Review.
The post-transplant lymphoproliferative disorders (PTLD) are a diverse group of potentially life-threatening conditions affecting organ transplant recipients. ...
The post-transplant lymphoproliferative disorders (PTLD) are a diverse group of potentially life-threatening con …
Post-transplant lymphoproliferative disorder.
Kalinova L, Indrakova J, Bachleda P. Kalinova L, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Dec;153(4):251-7. doi: 10.5507/bp.2009.043. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009. PMID: 20208963 Review.
BACKGROUND: Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a serious complication of solid organ transplantation in both children and adults. ...Search terms included posttransplant lymphoproliferative disorder, immuno …
BACKGROUND: Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a serious complication of solid o …
Post-transplant lymphoproliferative disorder.
Basgoz N, Preiksaitis JK. Basgoz N, et al. Infect Dis Clin North Am. 1995 Dec;9(4):901-23. Infect Dis Clin North Am. 1995. PMID: 8747772 Review.
This article discusses the virology of Epstein-Barr virus (EBV) and provides an overview of the disease states associated with the virus, describes how the immunology of EBV infection provides for control in the normal host, and reviews what is currently known about post- …
This article discusses the virology of Epstein-Barr virus (EBV) and provides an overview of the disease states associated with the virus, de …
Post-transplant lymphoproliferative disorder.
Loren AW, Tsai DE. Loren AW, et al. Clin Chest Med. 2005 Dec;26(4):631-45, vii. doi: 10.1016/j.ccm.2005.06.014. Clin Chest Med. 2005. PMID: 16263402 Review.
Post-transplant lymphoproliferative disorder (PTLD) is an increasingly recognized complication of solid organ and hematopoietic stem cell transplantation. ...
Post-transplant lymphoproliferative disorder (PTLD) is an increasingly recognized complication of solid organ an
Post-transplant lymphoproliferative disorder with cutaneous involvement: A series of four cases.
Ferreira MCC, Arai Seque C, Enokihara MMSES, Batista MD, Tomimori J, Porro AM. Ferreira MCC, et al. Clin Transplant. 2021 Feb;35(2):e14162. doi: 10.1111/ctr.14162. Epub 2020 Dec 13. Clin Transplant. 2021. PMID: 33217057 Review.
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLD) are lymphoid proliferations associated with post-transplant immunosuppression. ...
BACKGROUND: Post-transplant lymphoproliferative disorders (PTLD) are lymphoid proliferations associated with …
Management of Resistant Post-transplant Lymphoproliferative Disorder: CAR-T Is a New Option.
Styczynski J, Sadlok J, Styczynski T, Marjanska A, Richert-Przygonska M. Styczynski J, et al. Anticancer Res. 2022 Nov;42(11):5181-5186. doi: 10.21873/anticanres.16024. Anticancer Res. 2022. PMID: 36288856 Review.
This is a review of the therapeutic options for resistant/refractory post-transplant lymphoproliferative disorder (PTLD) in relation to Chimeric antigen receptor-T cell (CAR-T) therapy. ...
This is a review of the therapeutic options for resistant/refractory post-transplant lymphoproliferative disorder
3,701 results